OncoMatch/Clinical Trials/NCT04589754
Adriamycin and Ifosfamide Combined With Sintilimab
Is NCT04589754 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Sintilimab plus chemotherapy and Adriamycin-based chemotherapy for soft tissue sarcoma.
Treatment: Sintilimab plus chemotherapy · Adriamycin-based chemotherapy — The aim of this study was to explore the efficacy and safety of adriamycin and ifosfamide combined with sintilimab versus chemotherapy in the treatment of advanced or unresectable soft tissue sarcoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
Patients who had previously received anti-PD-1 / PD-L1 antibody therapy
Cannot have received: anti-PD-L1 therapy
Patients who had previously received anti-PD-1 / PD-L1 antibody therapy
Cannot have received: systemic anti-tumor therapy
Systemic anti-tumor therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or mitomycin C within 6 weeks prior to the trial drug treatment) was planned within 4 weeks before enrollment or during the study period
Cannot have received: extended field radiotherapy
Over extended field radiotherapy (ef-rt) was performed within 4 weeks before admission
Cannot have received: limited field radiotherapy
limited field radiotherapy (rfrt) was performed within 2 weeks before grouping
Cannot have received: other clinical trial anti-tumor drugs
Patients who participated in other clinical trials of anti-tumor drugs within 28 days before enrollment
Lab requirements
Blood counts
Hemoglobin (HB) ≥ 90g/L; ANC ≥ 1.5 × 10^9/L; Platelet (PLT) ≥ 80 × 10^9/L
Kidney function
Serum creatinine (CR) ≤ 1.5x ULN or creatinine clearance rate (CCR) ≥ 60 ml/min
Liver function
Total bilirubin (TBIL) ≤ 1.5x ULN; ALT and AST ≤ 2.5x ULN (≤ 5x ULN with liver metastasis)
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ lower limit of normal value (50%)
Blood routine examination standard ... Hemoglobin (HB) ≥ 90g / L; The absolute value of neutrophil (ANC) ≥ 1.5 × 109 / L; Platelet (PLT) ≥ 80 × 109 / L. Biochemical examination ... TBIL ≤ 1.5x ULN; ALT and AST ≤ 2.5x ULN (≤ 5x ULN with liver metastasis); Serum creatinine (CR) ≤ 1.5x ULN or CCR ≥ 60ml / min; Doppler ultrasound evaluation: LVEF ≥ lower limit of normal value (50%).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04589754 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, anti-PD-L1 therapy, systemic anti-tumor therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages